KI23057 is a competitive, orally active tyrosine kinase inhibitor that inhibits the phosphorylation of K-samII/FGF-R2, VEGF-R1, VEGF-R2, PDGF-Rβ, and c-Kit with IC50 values of 88, 69, 83, 100, and 480 nM, respectively; it suppresses the proliferation of scirrhous gastric cancer cells OCUM-2MD3 and OCUM-8 and induces apoptosis; it exhibits antitumor activity in mouse models.